AstraZeneca Investor Day Presentation Deck
AZ poised to become a leader in GI cancers
Late-stage clinical programmes
SIMFINZI
durvalumab
Injection for Intravenous Use 50 mg/mL
ENHERTUⓇ
fam-trastuzumab deruxtecan-nxki
20 mg/mL INJECTION FOR INTRAVENOUS USE
EMERALD-1: locoregional HCC; data H2 2022
EMERALD-2: adjuvant HCC; data 2022 +
MATTERHORN: resectable gastric / GEJ; data 2022+
KUNLUN: locally-advanced oesophageal; data 2022+
DESTINY-Gastric03: HER2+ gastric / GEJ; data 2022+
DESTINY-Gastric04: 2L gastric / GEJ; data 2022+
DESTINY-Gastric06: 3L HER2+ CN; data 2022+
DESTINY-CRC02: 3L HER2+ CN; data 2022+
DESTINY-PT01: CRC, liver and gastric; data 2022+
DESTINY-PT02: BTC and pancreatic; data 2022+
Selected early-stage
5
datopotamab deruxtecan (TROP2 ADC)
HER2-ve gastric/GEJ and oesophageal
AZD8205 (B7H4 ADC)
cholangiocarcinoma
oleclumab (CD73 mAb)
pancreatic
AZD0171 (LIF1 mAb)
pancreatic
31 GEJ = gastroesophageal junction adenocarcinoma; HER2 = human epidermal growth factor receptor 2; CN = China; PT= pan-tumor; TROP2 = trophoblast cell surface antigen 2; HER2-ve = HER2-negative; B7H4 = v-set domain-
containing T-cell activation inhibitor 1; ADC = antibody drug conjugate; CD73 = cluster of differentiation 73; mAb = monoclonal antibody; LIF1 = leukaemia inhibitory factor 1.
4View entire presentation